US EditionRace Oncology accelerates gamechanging cancer drug
Summary by themarketonline.com.au
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Race Oncology accelerates gamechanging cancer drug
In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s “safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. Dr Smith told HotCopper about “reformulating” old drugs to put together the…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
